Daiichi in ADC deal for Glycotope's anti-mucin antibody

Glycotope GmbH (Berlin, Germany) granted Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive, worldwide rights to develop and commercialize an antibody-drug conjugate to treat cancer using Glycotope's gatipotuzumab (formerly PankoMab-GEX).

Glycotope will receive an undisclosed upfront payment and is eligible for development and sales milestones, plus royalties. Daiichi gained the option to license gatipotuzumab in 2017. ...